Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia"
DOI: 10.1038/s41375-022-01532-1
Abstract: Some patients with acquired pure red cell aplasia (aPRCA) have no response or are intolerant to cyclosporine A. From April 2017 to August 2020, patients diagnosed with aPRCA at Peking Union Medical College Hospital who… read more here.
Keywords: sirolimus effective; red cell; cell aplasia; pure red ... See more keywords